deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT03032783

A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Conditions Hematopoietic and Lymphoid Cell Neoplasm
Interventions Allogeneic Hematopoietic Stem Cell Transplantation Cyclophosphamide Donor Lymphocyte Infusion Mycophenolate Mofetil Tacrolimus Total-Body Irradiation
Updated 18 times since 2017 Last updated: Jan 27, 2026 Started: Jan 31, 2017 Primary completion: Dec 2, 2025 Completion: Dec 2, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03032783, this PHASE2 trial focuses on Hematopoietic and Lymphoid Cell Neoplasm and remains completed. Sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, it has been updated 18 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Mar 2018 · 10 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~Jan 2020 · 10 months · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Sep 2022 · 11 months · monthly snapshot~Sep 2022 – ~Jun 2023 · 9 months · monthly snapshot~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – ~Jul 2025 · 30 days · monthly snapshot~Jul 2025 – ~Nov 2025 · 4 months · monthly snapshot~Nov 2025 – ~Feb 2026 · 3 months · monthly snapshot~Feb 2026 – present · 7 months · monthly snapshot

Change History

18 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Nov 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Jul 2025 — Nov 2025 [monthly]

    Recruiting PHASE2

  4. Jun 2025 — Jul 2025 [monthly]

    Recruiting PHASE2

  5. Sep 2024 — Jun 2025 [monthly]

    Recruiting PHASE2

▶ Show 13 earlier versions

  1. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  2. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE2

  3. Jun 2023 — Jul 2024 [monthly]

    Recruiting PHASE2

  4. Sep 2022 — Jun 2023 [monthly]

    Recruiting PHASE2

  5. Oct 2021 — Sep 2022 [monthly]

    Recruiting PHASE2

  6. Jan 2021 — Oct 2021 [monthly]

    Recruiting PHASE2

  7. Feb 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  8. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE2

  9. Mar 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  10. Jun 2018 — Mar 2019 [monthly]

    Recruiting PHASE2

  11. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  12. May 2017 — Mar 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  13. Feb 2017 — May 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Jan 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Data source: Thomas Jefferson University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations